NEOG — Neogen Corporation

Is NEOG overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Oversold As of November 17, 2026

Neogen Corporation (NEOG) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $10.88. The rating moved from Neutral to Oversold on November 6, 2026.

See all oversold Healthcare stocks →

AI analysis

Neogen Corporation (NEOG) is a diversified diagnostics and food/animal safety company with recurring consumable revenue and a history of strategic acquisitions to broaden its addressable markets. Financial health is contingent on steady testing volumes and margin recovery from consumables and services; operating leverage could boost profitability if demand stabilizes. Near-term catalysts are limited to quarterly results, contract wins, or accretive acquisitions, while downside stems from ag-cycle softness, regulatory shifts, and integration risks. Market perception is muted with balanced sentiment amid a cautious risk-on environment, suggesting limited conviction until clearer earnings or strategic execution signals emerge.

Key factors

  • Neogen Corporation (NEOG) has a diversified product mix across food safety and animal health diagnostics, which supports recurring revenue streams and resilience versus single-product biotech peers.
  • Stable demand drivers: ongoing regulatory and industry focus on food safety testing and biosecurity drives steady consumable and reagent repeat purchases.
  • Margin recovery potential from higher-margin consumables and services, plus operational leverage if volume normalizes following recent macro softness.
  • M&A track record and bolt-on acquisitions expand addressable market and cross-sell opportunities in specialty diagnostics and distribution channels.
  • Reasonable valuation relative to growth peers; current price implies modest near-term growth expectations, leaving upside if execution or demand re-accelerates.
  • Limited short-term market catalysts make near-term moves tied to quarterly results, incremental contract wins, or acquisition announcements.
  • Exposure to global ag/food chains provides geographic diversification but also opens international growth avenues if executed well.

Risks

  • Cyclicality of agriculture and livestock markets can depress testing volumes and diagnostic demand in economic slowdowns.
  • Regulatory changes in food processing and trade policies could reduce testing frequency or shift testing to different providers.
  • Customer concentration in certain end markets or large account pricing pressure could compress margins.
  • Supply chain disruptions or cost inflation for reagents, components, and logistics could hurt gross margins and delivery timelines.
  • Execution risk on integration of acquisitions and conversion of those assets into sustainable organic growth.
  • Foreign exchange exposure and geopolitical trade risks in key international markets may create revenue volatility.
  • Competitive pressure from larger diagnostics and lab-service providers may limit pricing power or slow market share gains.
  • Limited public social sentiment and analyst coverage increases the chance of volatility on surprises or unexpected earnings prints.

See today's live rating, score and targets

Members see the live hourly rating for NEOG — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.